Physician profile
Tracy E Mullins
NPI 1417908526
$2,580.68
in general payments reported to CMS, 2019-2025
23 companies · $1,083 in 2025
The $1,083 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $94.20 · 2022: $336 · 2023: $672 · 2024: $396 · 2025: $1,083.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,983 · Education: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,982.75 |
| Education | $167.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $596.16 | 2023-2025 | Gemtesa |
| Abbvie INC. | $288.93 | 2022-2025 | |
| Janssen Biotech, INC. | $215.99 | 2023-2025 | Erleada, Akeega |
| Endo Pharmaceuticals INC. | $205.63 | 2022-2024 | Xiaflex, Aveed, Edex |
| Urogen Pharma, INC. | $188.25 | 2025 | |
| 180 Medical, INC. | $170.35 | 2024-2025 | |
| Astellas Pharma US INC | $164.98 | 2021-2025 | |
| Urovant Sciences INC | $126.18 | 2022 | |
| Endo USA, INC. | $108.26 | 2024-2025 | Xiaflex, Aveed |
| Teleflex LLC | $90.90 | 2023-2025 | Urolift, Barrigel |
| C. R. Bard, INC. & Subsidiaries | $64.56 | 2025 | Personal Catheter Intermittent Catheter, Purewick Female External Catheter |
| Boston Scientific Corporation | $54.13 | 2025 | General - Bph, General - Erectile Dysfunction |
| Dentsply Ih Ab | $52.29 | 2025 | Lofric |
| Novartis Pharmaceuticals Corporation | $41.74 | 2025 | |
| Tolmar Pharmaceuticals, INC. | $41.03 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abc Home Medical Supply, INC. | $34.68 | 2025 | |
| Myriad Genetic Laboratories, INC. | $34.24 | 2022 | |
| Tolmar, INC. | $19.44 | 2025 | Eligard, Jatenzo |
| Axonics, INC. | $19.40 | 2023 | Bulkamid, Axonics |
| Ferring Pharmaceuticals INC. | $17.25 | 2025 | Adstiladrin |
| Pfizer INC. | $16.10 | 2022 | |
| Laborie Medical Technologies Corp. | $15.51 | 2021 | |
| Ambu INC. | $14.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Mullins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.